By Helena Smolak


GSK said that a plaintiff in an Illinois lawsuit against the company voluntarily dismissed her case, one of many legal disputes alleging its discontinued drug Zantac caused cancer.

The British pharmaceutical giant said late Monday that the trial was scheduled to start yesterday in Illinois, adding that it didn't reach a settlement nor made any payments in exchange for the voluntary case dismissal.

Separately, as expected, the company filed an appeal with the Delaware Supreme Court, challenging a court's decision last week to allow jury trials and expert testimony in Zantac litigation within the state. A court earlier this month found what it said was evidence that links its Zantac heartburn drug to cancer, allowing jury trials for these cases. GSK anticipates a decision on whether an interlocutory review and hearing of the appeal will be granted this year.

GSK said that the Superior Court's ruling concerning its Zantac drug, jointly owned by several pharmaceutical companies, contradicts the application of the Daubert standard--a rule governing the admissibility of expert testimony--in Delaware and federal courts.


Write to Helena Smolak at helena.smolak@wsj.com


(END) Dow Jones Newswires

06-11-24 0225ET